Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Treasury Shares changed N/A to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2024, which is 4180.73% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Treasury Shares is $13.8 million.
  • Xeris Biopharma Holdings' 5-year Treasury Shares high stood at $16.4 million for Q4 2024, and its period low was $2.1 million during Q3 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Treasury Shares had a median value of $13.8 million in 2025 and averaged $11.2 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Treasury Shares soared by 12032.95% in 2023, and later soared by 4180.73% in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Treasury Shares stood at $2.1 million in 2021, then soared by 154.76% to $5.3 million in 2022, then surged by 120.33% to $11.6 million in 2023, then surged by 41.81% to $16.4 million in 2024, then fell by 16.1% to $13.8 million in 2025.
  • Its Treasury Shares stands at $13.8 million for Q3 2025, versus $14.5 million for Q2 2025 and $15.1 million for Q1 2025.